344
Participants
Start Date
April 7, 2024
Primary Completion Date
August 31, 2027
Study Completion Date
August 31, 2028
Lisaftoclax (APG-2575)
QD, oral administration, every 28 days for a dosing cycle.
Acalabrutinib
BID, oral administration, every 28 days for a dosing cycle.
Fludarabine
Every 28 days for a treatment cycle, administration of 6 cycles.
Cyclophosphamide，CTX
Every 28 days for a treatment cycle, administration of 6 cycles.
Rituximab
Every 28 days for a treatment cycle, administration of 6 cycles.
Chlorambucil
Every 28 days for a treatment cycle, administration of 6 cycles.
NOT_YET_RECRUITING
The First Affiliated Hospital of Bengbu Medical College, Bengbu
RECRUITING
Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin
NOT_YET_RECRUITING
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
Henan Provincial Cancer Hospital, Zhengzhou
NOT_YET_RECRUITING
Guangdong Provincial People's Hospital, Guangzhou
NOT_YET_RECRUITING
Nanfang Hospital of Southern Medical University, Guangzhou
Lead Sponsor
Ascentage Pharma Group Inc.
INDUSTRY